• Biosimilars
  • Drug Development/R&D
  • All Topics
OHE OHE
Newsletter SignupSubscribe

News & Insights
  • News
  • Events
  • Insights
  • Bulletin
  • News
  • Events
  • Insights
  • Bulletin

News & Insights

  • News
  • Events
  • Insights
  • Bulletin
Newsletter SignupSubscribe
  • News
  • Events
  • Insights
  • Bulletin

Close
OHE OHE
  • Research & Publications
  • News & Insights
  • Education
  • Innovation Policy Prize
  • Events
  • About Us
  • OHE Experts
  • Contact Us
Newsletter SignupSubscribe

Research & Publications

All Publications

Filter by:
  • Antimicrobial Resistance (AMR)
  • Biosimilars
  • Cell and Gene Therapies
  • Chronic Diseases
  • Combination Therapies
  • COVID-19 Research
  • Digital Health
  • Drug Development/R&D
  • Emerging Markets
  • EQ-5D and PROMs
  • Health Care Systems
  • Health Data and Statistics
  • Health Technology Assessment
  • Precision Medicine
  • Real World Evidence
  • Use of Medicines
  • Value-Based Pricing
  • Vaccine Research
  • Economics of Innovation
  • Measuring and Valuing Outcomes
  • Policy, Organisation and Incentives in Health Systems
  • Value, Affordability and Decision Making

News & Insights

  • News
  • Events
  • Insights
  • Bulletin

Education

  • Education Hub
  • OHE Graduate School
  • EVIA Programme

Innovation Policy Prize

  • The Prize Fund
  • 2022 Prize Fund

Latest Research & Publications

Proposal for a General Outcome-based Value Attribution Framework for Combination Therapies

CombTher_Adobe_photoguns_portrait
Read more
© photoguns
  • Digital Health

Navigating the Landscape of Digital Health – United Kingdom

Healthcare_Adobe_elenabsl
Read more

2021 OHE Annual Report to the Charity Commission

charityreport_lina-trochez-unsplash_landscape
Read more
© Lina Trochez/Unsplash

Supporting the Era of Green Pharmaceuticals in the UK

Sustainability_AdobeStock_270582392_landscape
Read more

Quality of life and wellbeing in individuals with experience of fertility problems and assisted reproductive techniques

Quality of life assisted reproduction Cover
Read more
  • Cell and Gene Therapies
  • Value, Affordability, and…

Health Technology Assessment of Gene Therapies: Are Our Methods Fit for Purpose?

gene_therapies_national-cancer-institute-unsplash_landscape
Read more
© NCI/Unsplash
  • Drug Development/R&D
  • Economics of Innovation
  • Health Policy and Regulation

Limitations of CBO’s Simulation Model of New Drug Development as a Tool for Policymakers

CBO-US_mayer-tawfik-K4Ckc0AxgDI-unsplash_landscape
Read more
© Mayer Tawfik/Unsplash
  • Measuring and Valuing Outcomes

When Generic Measures Fail to Reflect What Matters to Patients: Three Case Studies

PROMS_unsplash_National Cancer Institute_landscape
Read more
© NCI/Unsplash
Close
OHE
  • All Publications

    Filter by:
    • Antimicrobial Resistance (AMR)
    • Biosimilars
    • Cell and Gene Therapies
    • Chronic Diseases
    • Combination Therapies
    • COVID-19 Research
    • Digital Health
    • Drug Development/R&D
    • Emerging Markets
    • EQ-5D and PROMs
    • Health Care Systems
    • Health Data and Statistics
    • Health Technology Assessment
    • Precision Medicine
    • Real World Evidence
    • Use of Medicines
    • Value-Based Pricing
    • Vaccine Research
    • Economics of Innovation
    • Measuring and Valuing Outcomes
    • Policy, Organisation and Incentives in Health Systems
    • Value, Affordability and Decision Making
    • News
    • Events
    • Insights
    • Bulletin
    • Education Hub
    • OHE Graduate School
    • EVIA Programme
    • The Prize Fund
    • 2022 Prize Fund
  • Events
  • About Us
  • OHE Experts
  • Contact Us
Newsletter SignupSubscribe
Back
  • News
11 min read 9th July 2018

What are the Economic Implications of Moving Away from Paying a Single Price for a Single Drug?

The OHE has published a report exploring the impact on payers, patients and innovators of differential prices for different uses of pharmaceuticals. Our latest Research Paper explores the impact on payers, patients and innovators of differential prices for different uses…

Share:
  •  Twitter
  •  LinkedIn
  •  Facebook
  • has-icon Email

The OHE has published a report exploring the impact on payers, patients and innovators of differential prices for different uses of pharmaceuticals.

Our latest Research Paper explores the impact on payers, patients and innovators of differential prices for different uses of pharmaceuticals.
 
The value of a drug can vary substantially depending on what it is used for. A single drug may be useful at different stages of a disease, when used in combination with another drug, or when used for a different disease entirely. Increasingly, drugs are being licensed for multiple indications, yet assessments of value are, in most countries, based on a single price for a single drug. Where the clinical value derived from a drug varies across contexts, the relationship between price and value also varies.
 
Innovative payment models – which could permit different levels of payment for different uses – have been proposed. These could range from outcome-based payments at the individual patient level, to a suite of different prices for different uses/indications. Whatever the format, the proposal is to allow differential pricing for pharmaceuticals. The term indication-based pricing (IBP) is often used in medical and health economics literature to refer to this concept. In an OHE Consulting report published last month, Towse, Cole and Zamora provided a review of the current debate around IBP in the literature, as well issues affecting its potential use in five major European countries and the U.S.
 
In the report published today, for which research funding was provided by IQVIA, OHE authors Amanda Cole, Adrian Towse, and Paula Lorgelly, along with King’s College London collaborator Professor Richard Sullivan, address the question: What are the economic implications of an alternative to single-price payments for pharmaceuticals?   
 
Indication-based pricing offers the opportunity to better align payment with value, but the impact on patients, payers, and incentives for innovation are not clear-cut. Two key papers offer competing perspectives. Bach (2014) described the potential for IBP to increase transparency and illustrated how IBP could lead to lower prices for lower value indications, while Chandra and Garthwaite (2017) argued that IBP would lead to higher prices overall. The key differences arose from assumptions as to where (single) prices are currently set, and the extent to which IBP could expand patient access by allowing further indications to be developed.
 
In our new Research Paper, we describe how the implications of a move away from a single-price model toward indication-based pricing (or similar) can be considered in terms of the short-term (static) effect, and the long-term (dynamic) effect. In the short term, economic theory indicates that indication-based pricing can improve welfare if it means that more patients can access the drug as a result, if, for example, in the single-price scenario, certain indications are not developed in order to protect price in higher value indications. However, prices may also go up for some indications (if the single price is not set at the highest value indication), with a transfer of some economic surplus from payers to manufacturers. 
 
Longer-term ‘dynamic’ effects are often overlooked, yet the impact on research and development (R&D) and incentives for innovation must be considered. Firstly, additional indications that provide cost-effective treatment are likely to be developed. Secondly, scientific progress stimulates competition and often leads to several products coming to market in a therapy class. This is particularly the case in recent developments in oncology. We propose that a move to indication-based pricing would: (i) provide efficient R&D incentives which stimulate the development of new indications and greater access for patients, and (ii) increase price competition at indication-level, which could lead to lower prices. The latter effect would transfer surplus from innovators to the payer.  
 
In order to explore the potential impact of competition, we identify two classes of cancer therapy: tyrosine-kinase inhibitors (TKIs) and PD-1/PD-L1 inhibitors and show how competing products and competing indications have developed over time. In the case of the PD-1/PD-L1 inhibitors, additional indications are currently in development with more competing therapies expected to enter the market for several further cancer types. We illustrate how competition by indication in the PD-1/PD-L1 space could, in theory, reduce prices below the value-based price. 
 
The report also briefly sets out the challenges of implementing IBP. As well as having an economic regulatory regime that supports the use of IBP and prevents arbitrage between low-value and high-value uses, the key challenges are informational. At a minimum, data that tracks use by patient is needed, at least for a sample of patients. Collecting real-world data on the treatment outcomes achieved by patients will increasingly be required, again, at least for a sample of patients. However, proxies for, or surrogate measures of, outcomes can also be used to support the use of IBP, for example on patient duration of treatment as a proxy for patient benefit. Pragmatic approaches have the potential to address health care needs whilst achieving better value for money.
 
Download the full report here.
 
Citation
 
Cole, A., Towse, A., Lorgelly, P., and Sullivan, R., 2018. Economics of Innovative Payment Models Compared with Single Pricing of Pharmaceuticals. OHE Research Paper, London: Office of Health Economics.
 
Related Research
 
Towse, A., Cole, A., and Zamora, B., 2018. The Debate on Indication-Based Pricing in the U.S. and Five Major European Countries. OHE Consulting Report, London: Office of Health Economics. RePEc
 
Mestre-Ferrandiz, J., Towse, A., Dellamano, R. and Pistollato, M., 2015. Multi-indication Pricing: Pros, Cons and Applicability to the UK. OHE Seminar Briefing, London: Office of Health Economics. RePEc
 
Towse, A., Pistollato, M., Mestre-Ferrandiz, J., Khan, Z., Kaura, S. and Garrison, L., 2015. European Union Pharmaceutical Markets: A Case for Differential Pricing? International Journal of the Economics of Business, 22(2), pp.263-275. DOI | RePEc
 
 
  • Value-Based Pricing
  • Economics of Innovation
  • Pricing and Reimbursement

Related News

  • News
  • December 2020

Should We ‘Drop Dead’ from Health State Valuation?

Read more
  • News
  • September 2020

Cornerstones of ‘Fair’ Drug Coverage

Read more
  • News
  • September 2020

Establishing a Reasonable Price for an Orphan Drug

Read more
  • News
  • June 2020

The 2020 OHE Annual Lecture Explores the Question: How Should the World Pay for a COVID-19 Vaccine?

Read more
footer_ohe_logo

Leading intellectual authority on global health economics

Sign Up for the OHE News Bulletin

Newsletter SignupStart Sign Up

Research & Publications

News & Insights

Innovation Policy Prize

Education

Events

About Us

OHE Experts

Contact Us

Sign Up for the OHE News Bulletin

Newsletter SignupStart Sign Up

The Office of Health Economics (OHE) is a company limited by guarantee registered in England and Wales (registered number 09848965) and its registered office is at 2nd Floor Goldings House, Hay’s Galleria, 2 Hay’s Lane, London, SE1 2HB.

Terms & Conditions

Privacy Policy

Cookies Policy

© 2023 Website Design

An error has occurred, please try again later.An error has occurred, please try again later.

We are using cookies to give you the best experience on our website.

You can find out more about which cookies we are using or switch them off in settings.

 Twitter
 Facebook
 LinkedIn
 Copy
 Email
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.

Strictly Necessary Cookies

Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.

If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.

3rd Party Cookies

This website uses Google Analytics to collect anonymous information such as the number of visitors to the site, and the most popular pages.

Keeping this cookie enabled helps us to improve our website.

Please enable Strictly Necessary Cookies first so that we can save your preferences!